17.75
1.93%
-0.35
Handel nachbörslich:
16.87
-0.88
-4.96%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$18.10
Offen:
$18.05
24-Stunden-Volumen:
863.48K
Relative Volume:
0.50
Marktkapitalisierung:
$1.39B
Einnahmen:
$198.84M
Nettoeinkommen (Verlust:
$-111.40M
KGV:
-3.927
EPS:
-4.52
Netto-Cashflow:
$-322.28M
1W Leistung:
-3.38%
1M Leistung:
+16.55%
6M Leistung:
+183.55%
1J Leistung:
+154.66%
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
2023-11-20 | Eingeleitet | Citigroup | Neutral |
2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
2023-07-21 | Eingeleitet | JP Morgan | Overweight |
2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
2023-05-22 | Eingeleitet | TD Cowen | Outperform |
2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
2023-03-01 | Eingeleitet | Guggenheim | Buy |
2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
2022-12-14 | Eingeleitet | Stifel | Hold |
2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia
Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com
Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St
Travere: Q3 Earnings Snapshot - The Washington Post
Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia
Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com
Travere Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com
TD Cowen reiterates Buy on Travere shares after PARASOL findings By Investing.com - Investing.com Canada
Semanteon Capital Management LP Purchases Shares of 36,699 Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere presents data reinforcing clinical benefit of FILSPARI in IgAN - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 - The Manila Times
TSX Income Trust Index (RTCM) QuotePress Release - The Globe and Mail
(TVTX) Trading Report - Stock Traders Daily
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines
Travere Therapeutics (TVTX) to Release Quarterly Earnings on Thursday - MarketBeat
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money' - Yahoo Finance
Wall Street Analysts See a 26.27% Upside in Travere (TVTX): Can the Stock Really Move This High? - MSN
Travere Therapeutics to Report Third Quarter 2024 Financial Results - The Manila Times
Travere Therapeutics (NASDAQ:TVTX) Shares Gap UpTime to Buy? - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Upgraded at Wells Fargo & Company - MarketBeat
Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings) - Benzinga
Wells Fargo raises Travere Therapeutics stock to Overweight rating By Investing.com - Investing.com Canada
State Street Corp's Strategic Reduction in Travere Therapeutics Holdings - GuruFocus.com
TVTX stock soars to 52-week high, hits $18.63 amid robust gains - Investing.com Australia
Travere Therapeutics (NASDAQ:TVTX) Hits New 1-Year HighHere's Why - MarketBeat
TVTX stock soars to 52-week high, hits $18.63 amid robust gains By Investing.com - Investing.com South Africa
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy - StockTitan
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - PR Newswire
Breaking Down Travere Therapeutics: 23 Analysts Share Their Views - Benzinga
Travere Therapeutics (NASDAQ:TVTX) Earns Sector Outperform Rating from Analysts at Scotiabank - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Investing in Travere Therapeutics Inc (TVTX) Is Getting More Attractive - Knox Daily
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024 - The Manila Times
Travere Awaits FDA Ruling On Rare Kidney Disease Drug - RTTNews
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Travere Therapeutics Inc-Aktie (TVTX) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
LYONS GARY A | Director |
Oct 04 '24 |
Sale |
14.73 |
40,000 |
589,101 |
51,000 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):